Scribe Therapeutics Inc. (NASDAQ:SCTX)
| Market Cap | 249.28M-28.9% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 16.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 861,395 |
| Open | 18.55 |
| Previous Close | 17.96 |
| Day's Range | 15.12 - 18.55 |
| 52-Week Range | 13.50 - 39.60 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 51.75(+235.93%) |
| Earnings Date | Dec 2, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About SCTX
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
$SCTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SCTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SCTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SCTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SCTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SCTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SCTX
| ETF | Est. Holding Size |
|---|---|
| ARKGARK Genomic Revolution ETF | $22.41M |
| VTIVanguard Morningstar Total Stock Market ETF | $5.35M |
| IWMiShares Russell 2000 ETF | $4.40M |
| VXFVanguard Extended Market ETF | $1.93M |
| VTWOVanguard Russell 2000 ETF | $1.04M |
| IWOiShares Russell 2000 Growth ETF | $948.99K |
Estimated from each fund’s disclosed top holdings × AUM
SCTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SCTX’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.